The Remove study is investigating the company’s Catuvab device, designed to remove cancerous cells from a patient’s blood whilst undergoing cancer related surgery. Credit: Shutterstock / PIJITRA PHOMKHAM.

German medical technology company Lindis Blood Care has announced that the last patient participating in its trial of the removal of tumour cells from surgical shed blood has completed the trial with top-line results expected in early 2024.

The study, entitled the Remove study, is investigating the company’s Catuvab device, designed to remove cancerous cells from a patient’s blood whilst undergoing cancer-related surgery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The company has said that its confirmational open-label multicenter clinical study was able to enrol 130 patients and is one of the largest studies of its kind examining the use of a medical device for the removal of tumour cells in an intraoperative blood salvage (IBS) procedure.

Catuvab is intended to be used in surgeries involving epithelial cell adhesion molecule-positive tumours, a tumour marker that can be found in many of the most common carcinomas, including ovarian, colon, gastric and prostate cancer. The benefit of the IBS procedure is to allow the patient to receive their blood back as part of a high-risk cancer surgery, significantly reducing risk to the patient as opposed to relying on donor blood.

Lindis Blood Care co-founder Franzpeter Bracht commented: “We are pleased to announce the completion of our confirmatory study, which represents an important milestone towards certification of our device and brings us one step closer to making Catuvab and autologous blood transfusion available to cancer patients.”

See Also:

The Remove trial is intended to form the basis of Lindis Blood Care’s bid to achieve a European CE mark for its device, as well as in hopes of achieving full clearance from the US Food and Drug Administration (FDA)

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It follows after a competing US company, Illinois-based Ecomed Solutions, launched their own surgical blood management device in 2019, similarly intended to collect a patient’s lost blood during surgery and return it to their body in a process known as cell salvage.

Lindis Blood Care co-founder Horst Lindhofer said: “Blood is a precious and scarce resource. Being able to use a cancer patient’s own blood in the operation room by avoiding the risk of metastases from remaining tumour cells would be a much-needed transformation in the patient blood management landscape.”